An Open-label, Randomised, 3-period, 3-treatment, Crossover, Single-centre, Single-dose, Bioavailability Study With Alternative Methods of Administration of Crushed Ticagrelor Tablets, 90 mg, Compared to Whole Ticagrelor Tablets, 90 mg, in Healthy Volunteer
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2015
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes; Coronary artery disease; Embolism and thrombosis; Peripheral arterial disorders
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2013 New trial record